ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: L08 • ACR Convergence 2020

    Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)

    Thomas MacDonald1, Isla Mackenzie1, George Nuki2 and Ian Ford3, 1University of Dundee, Dundee, Scotland, United Kingdom, 2University of Edinburgh, Edinburgh, Scotland, United Kingdom, 3University of Glasgow, Glasgow, Scotland, United Kingdom

    Background/Purpose: Febuxostat and allopurinol are uric acid lowering agents. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency (EMA) recommended a post-authorization…
  • Abstract Number: 0535 • ACR Convergence 2020

    Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists

    Jasvinder Singh1, John Richards2, Elizabeth Chang3, Toupin-April, Karine Toupin-April4 and Jennifer Barton5, 1University of Alabama at Birmingham, Birmingham, AL, 2Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 3Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, 4VA Portland Oregon, Portland, OR, 5Oregon University, Portland, OR

    Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…
  • Abstract Number: 0660 • ACR Convergence 2020

    Sodium-Glucose Co-Transporter-2 Inhibitors and the Risk for Gout – a Comparison Among Canagliflozin, Dapagliflozin and Empagliflozin

    Ana Beatriz Vargas-Santos1, Christine Peloquin2, Seoyoung Kim3 and Tuhina Neogi2, 1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, 2Boston University School of Medicine, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Sodium-glucose co-transporter-2 inhibitors (SGLT2-i) are anti-diabetic drugs that have a urate-lowering effect. SGLT2-i had a more favorable impact on gout risk than glucagon-like peptide-1…
  • Abstract Number: 0682 • ACR Convergence 2020

    Role of Inflammatory and Oxidative Stress Pathway Biomarkers in Renal Disease in Gout

    Fatima Alduraibi1, Karina Ricart1, Rakesh Patel1, Alexander Szalai1, Joshua Melnick2 and Jasvinder Singh1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Vestavia Hills, AL

    Background/Purpose: To understand the role of inflammatory cytokines and oxidative stress biomarkers in the renal disease in people with gout. We hypothesized that higher gout…
  • Abstract Number: 1472 • ACR Convergence 2020

    Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization

    Natalie McCormick1, Mark O'Connor1, Shelby Marozoff2, John Choi3, Aaron Leong1 and Hyon Choi4, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, Canada, 3Massachusetts General Hospital, Boston, 4Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear.  Observational studies have reported positive associations…
  • Abstract Number: 0600 • ACR Convergence 2020

    Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation

    Daniel DeMizio1, Guojing Wu2, Ying Wei2, Joan Bathon3 and Runsheng Wang4, 1Columbia University Irving Medical Center, Division of Rheumatology, Staten Island, NY, 2Columbia University Mailman School of Public Health, Department of Biostatistics, New York, NY, 3Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 4Columbia University Irving Medical Center, Division of Rheumatology, New York, NY

    Background/Purpose: There is growing evidence that both the prevalence of gout and its burden on healthcare costs has increased over recent decades. It has been…
  • Abstract Number: 0662 • ACR Convergence 2020

    Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

    Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%.   While gout flares…
  • Abstract Number: 0683 • ACR Convergence 2020

    Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate

    Yang Song1, Yan Xin1, Michael Weinblatt2, Jason Chamberlain1, Katie Obermeyer3, Lin Zhao3, Colleen Canavan3, Paul Peloso4 and Srini Ramanathan1, 1Horizon Therapeutics plc, South San Francisco, CA, 2Brigham and Women's Hospital, Boston, MA, 3Horizon Therapeutics plc, Lake Forest, IL, 4Horizon Therapeutics plc, Gurnee, IL

    Background/Purpose: In an open-label trial in adult patients with uncontrolled gout (MIRROR open-label [OL] trial) evaluating pegloticase co-treatment with methotrexate (MTX), 78.6% patients maintained serum…
  • Abstract Number: 1542 • ACR Convergence 2020

    The Role of Dual Energy Computed Tomography (DECT) in the Differentiation of Gout and Calcium Pyrophosphate Deposition Disease

    Dmitrij Kravchenko1, Pantelis Karakostas2, Peter Brossart3, Charlotte Behning4, Carsten Meyer1 and Valentin Schaefer5, 1Department of Interventional and Diagnostic Radiology, University Hospital Bonn, Bonn, Germany, Bonn, Germany, 2Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, Bonn, Germany, 3Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 4Institute for Medical Biometrics, Informatics and Epidemiology (IMBIE), University Hospital Bonn, Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 5Clinic ofInternal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, Bonn, Germany

    Background/Purpose: Differentiation of gout and calcium pyrophosphate deposition disease (CPPD) is sometimes difficult as patients often present with a similar clinical picture. Arthrocentesis and subsequent…
  • Abstract Number: 0646 • ACR Convergence 2020

    “An Apple Pie a Day Does Not Keep the Doctor Away”. Fictional Depictions of Gout in Contemporary Film and Television

    Rachel Murdoch1, Christina Derksen2, Keith Petrie1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Jacobs University, Bremen, Germany

    Background/Purpose: Views about gout as a self-inflicted condition of dietary excess can contribute to stigma and lead to ineffective management strategies. Fictional portrayals of illness…
  • Abstract Number: 0663 • ACR Convergence 2020

    Analysis of Common Gout Comorbidities in the UK Biobank Cohort Reveals Sex-Specific Effects and Genetic Differentiation

    Nicholas Sumpter1, Murray Cadzow2, Alexander So3, Richard Reynolds1 and Tony Merriman2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Dunedin, New Zealand, 3University of Lausanne, Lausanne, Switzerland

    Background/Purpose: This study aimed to estimate the extent to which gout associated genetic variants are associated with the presence/absence of common comorbidities in gout patients…
  • Abstract Number: 0684 • ACR Convergence 2020

    The Shrinking Toe: A Sign of Crystal Dissolution During Urate Lowering Treatment of Severe Gouty Arthropathy

    Thomas Bardin1, Nguyen Dinh Quang2, Hieu Le Nghia2, Tran Minh Khoi2, Hang Korng EA3, Valérie Bousson4 and Pascal Richette5, 1Université de Paris, INSERM U1132 and Hôpital Lariboisièe, Paris, France, Paris, France, 2Vien Gut Medical Center, Ho Chi Minh City, Vietnam, 3Universite de Paris, AP-HP, INSERM, paris, France, 4Lariboisière Hospital, Paris, France, 5Department of Rheumatology, Lariboisière Hospital, Paris, France

    Background/Purpose: Serum urate (SU) lowering has been reported to improve gout erosions. We observed that it may also lead to compaction of toe MTP or…
  • Abstract Number: 1550 • ACR Convergence 2020

    Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study

    Tristan Pascart1, Pascal Richette2, Sebastien Ottaviani3, Laurène Norberciak1, Hang Korng EA4, Frédéric Lioté5, Jérémy Ora6, Julie Legrand1, Valérie Bousson6, Elyas Mahdjoub7 and Jean--Francois Budzik8, 1GHICL, Lomme, France, 2Department of Rheumatology, Lariboisière Hospital, Paris, France, 3Rheumatology Department, Bichat hospital, APHP, Paris, France, 4Universite de Paris, AP-HP, INSERM, paris, France, 5AP-HP, Paris, France, 6Lariboisière Hospital, Paris, France, 7Bichat Hospital, Paris, France, 8University of Lille, Lille, France

    Background/Purpose: Dual-Energy computed tomography (DECT) and ultrasound are the two techniques able to identify and measure monosodium urate (MSU) crystal deposition, and both are considered…
  • Abstract Number: 0647 • ACR Convergence 2020

    Dual-energy CT versus Ultrasound, Alone or in Combination, for the Diagnosis of Gout: A Diagnostic Performance Study

    Jasvinder Singh1, Fabio Becce2, Jean--Francois Budzik3 and Tristan Pascart4, 1University of Alabama at Birmingham, Birmingham, AL, 2Lausanne University, Lausanne, Switzerland, 3University of Lille, Lille, France, 4Ghicl, Hôpital Saint-Philibert, department of rheumatology, Lomme, France

    Background/Purpose: To examine the diagnostic accuracy of dual-energy computed tomography (DECT) vs. ultrasound  or their combination for the diagnosis of gout.Methods: Using data from an…
  • Abstract Number: 0664 • ACR Convergence 2020

    Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

    Ana B. Arevalo1, Alba Munoz2, Faris Haddadin2, Karan Sud2, Gustavo Contreras2, Shane Murray2, Yousaf Ali2 and Edgar Argulian2, 1Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, 2Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York

    Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology